Literature DB >> 3484482

Low serum osteocalcin levels in glucocorticoid-treated asthmatics.

I R Reid, G E Chapman, T R Fraser, A D Davies, A S Surus, J Meyer, N L Huq, H K Ibbertson.   

Abstract

Serum osteocalcin (OC) levels were measured in 19 asthmatic patients receiving long term glucocorticoid therapy and in age- and sex-matched asthmatic patients not receiving this treatment. In the glucocorticoid-treated patients, the mean OC level was approximately 50% less than that in the control group (P less than 0.001), and there was a direct correlation between serum OC and 1,25-dihydroxyvitamin D [1,25-(OH)2D; r = 0.71; P less than 0.001]. Multiple regression analysis in a total of 39 glucocorticoid-treated patients indicated that OC correlated directly to 1,25-(OH)2D and inversely to glucocorticoid dose. There was no correlation between OC and 1,25-(OH)2D in the control group and no significant difference in mean serum 1,25-(OH)2D between the steroid-treated asthmatic patients and the asthmatic control patients. The effect of a 4-day course of oral 1,25-(OH)2D on serum OC was studied in six patients with glucocorticoid excess and six normal subjects. There was a similar percent increase in OC levels in both groups, though the basal concentrations and absolute increases were substantially less in the steroid-treated group. It is likely that the depression of serum OC in glucocorticoid-treated patients results from the reduction in the rate of bone formation induced by these hormones.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484482     DOI: 10.1210/jcem-62-2-379

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

1.  Sex does not influence serum osteocalcin levels in standardbred horses of different ages.

Authors:  O M Lepage; M Marcoux; A Tremblay; G Dumas
Journal:  Can J Vet Res       Date:  1992-10       Impact factor: 1.310

2.  The role of glucocorticoids and prostaglandin E2 in the recruitment of bone marrow mesenchymal cells to the osteoblastic lineage: positive and negative effects.

Authors:  A Scutt; P Bertram; M Bräutigam
Journal:  Calcif Tissue Int       Date:  1996-09       Impact factor: 4.333

Review 3.  Endogenous Glucocorticoids and Bone.

Authors:  Hong Zhou; Mark S Cooper; Markus J Seibel
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

Review 4.  Steroid osteoporosis.

Authors:  I R Reid
Journal:  Calcif Tissue Int       Date:  1989-08       Impact factor: 4.333

5.  Osteocalcin and bone mineral content in rheumatoid arthritis.

Authors:  A Peretz; J P Praet; S Rozenberg; D Bosson; J P Famaey; P Bourdoux
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

6.  Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism.

Authors:  Tara C Brennan-Speranza; Holger Henneicke; Sylvia J Gasparini; Katharina I Blankenstein; Uta Heinevetter; Victoria C Cogger; Dmitri Svistounov; Yaqing Zhang; Gregory J Cooney; Frank Buttgereit; Colin R Dunstan; Caren Gundberg; Hong Zhou; Markus J Seibel
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

7.  Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis.

Authors:  R Rizzoli; T Chevalley; D O Slosman; J P Bonjour
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

8.  Effects of prednisolone and deflazacort on osteocalcin metabolism in sheep.

Authors:  S L O'Connell; J Tresham; C L Fortune; W Farrugia; J G McDougall; B A Scoggins; J D Wark
Journal:  Calcif Tissue Int       Date:  1993-08       Impact factor: 4.333

Review 9.  Biochemical markers of bone turnover for the clinical investigation of osteoporosis.

Authors:  P D Delmas
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

10.  Acute effects of high-dose chemotherapy followed by bone marrow transplantation on serum markers of bone metabolism.

Authors:  K Carlson; B Simonsson; S Ljunghall
Journal:  Calcif Tissue Int       Date:  1994-12       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.